<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6775">5-Aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) compounds occasionally exacerbate diarrhoea in patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This is thought to be due to a secretory mechanism in most cases </plain></SENT>
<SENT sid="2" pm="."><plain>A patient with presumed intolerance to sulphasalazine and <z:chebi fb="0" ids="6775">5-ASA</z:chebi> preparations who developed endoscopic and histological evidence of disease relapse after a rectal challenge with <z:chebi fb="0" ids="6775">mesalazine</z:chebi> is reported </plain></SENT>
</text></document>